Results Snapshot
Figures in Cr
Consolidate Annual Results
Mar'26
Net Sales
869.15
Other Operating Income
0.00
Total Operating income
869.15
Raw Material Cost
315.46
Purchase of Finished goods
0.00
(Increase) / Decrease In Stocks
0.00
Employee Cost
154.34
Power Cost
0.00
Manufacturing Expenses
0.00
Selling and Distribution Expenses
0.00
Other Expenses
161.50
Total Expenditure (Excl Depreciation)
631.30
Operating Profit (PBDIT) excl Other Income
237.85
Other Income
3.11
Operating Profit (PBDIT)
240.96
Interest
25.33
Exceptional Items
-8.99
Gross Profit (PBDT)
206.64
Depreciation
53.28
Profit Before Tax
153.36
Tax
43.46
Provisions and contingencies
0.00
Profit After Tax
109.90
Extraordinary Items
0.00
Prior Period Expenses
0.00
Other Adjustments
0.00
Net Profit
109.90
Share in Profit of Associates
0.00
Minority Interest
-0.02
Other related items
0.00
Consolidated Net Profit
109.88
Equity Capital
12.55
Face Value
2.0
Reserves
1,137.18
Earnings per share (EPS)
17.51
Diluted Earnings per share
19.0
Operating Profit Margin (Excl OI)
27.37%
Gross Profit Margin
23.77%
PAT Margin
12.64%
Public Share Holdings (%)
0.0%
Pledged Promotor Holding (%)
0.0%
Annual Analysis Highlights
Analysis not available as Data has been published for only 1 period
Compare Annual Results Of Symbiotec Pharma With
Figures in Cr
Consolidate Annual Results
Change(INR)
Change(%)
Net Sales
869.15
4,359.02
-3,489.87
-80.06%
Other Operating Income
0.00
0.00
0.00
Total Operating income
869.15
4,359.02
-3,489.87
-80.06%
Raw Material Cost
315.46
2,298.68
-1,983.22
-86.28%
Purchase of Finished goods
0.00
201.00
-201.00
-100.00%
(Increase) / Decrease In Stocks
0.00
13.84
-13.84
-100.00%
Employee Cost
154.34
753.82
-599.48
-79.53%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
161.50
569.65
-408.15
-71.65%
Total Expenditure (Excl Depreciation)
631.30
3,836.99
-3,205.69
-83.55%
Operating Profit (PBDIT) excl Other Income
237.85
522.03
-284.18
-54.44%
Other Income
3.11
128.73
-125.62
-97.58%
Operating Profit (PBDIT)
240.96
650.76
-409.80
-62.97%
Interest
25.33
94.07
-68.74
-73.07%
Exceptional Items
-8.99
-20.02
11.03
55.09%
Gross Profit (PBDT)
206.64
536.67
-330.03
-61.50%
Depreciation
53.28
154.55
-101.27
-65.53%
Profit Before Tax
153.36
382.10
-228.74
-59.86%
Tax
43.46
125.70
-82.24
-65.43%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
109.90
256.40
-146.50
-57.14%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
109.90
256.40
-146.50
-57.14%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
-0.02
-1.21
1.19
98.35%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
109.88
255.19
-145.31
-56.94%
Equity Capital
12.55
30.62
-18.07
-59.01%
Face Value
2.00
2.00
0.00
Reserves
1,137.18
3,282.73
-2,145.55
-65.36%
Earnings per share (EPS)
17.51
16.67
0.84
5.04%
Diluted Earnings per share
19.00
16.67
2.33
13.98%
Operating Profit Margin (Excl OI)
27.37%
11.98%
0.00
15.39%
Gross Profit Margin
23.77%
12.31%
0.00
11.46%
PAT Margin
12.64%
5.88%
0.00
6.76%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 845.17 Cr
in Mar 2026Figures in Cr
Annual - Standalone Net Profit
Standalone Net Profit 115.83 Cr
in Mar 2026Figures in Cr
Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 240.64 Cr
in Mar 2026Figures in Cr
Annual - Interest
Interest 23.80 Cr
in Mar 2026Figures in Cr
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 28.47%
in Mar 2026Figures in %